Company intelligence / Profile preview
Citranvi Biosciences
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
Overview
Citranvi Biosciences has developed a proprietary multimeric protein vaccine platform licensed from the US Department of Defense, aiming to create first-in-class vaccines against human cytomegalovirus and Epstein-Barr virus. Both lead candidates are pre-clinical; no clinical trial results have been reported yet. The company’s approach has shown synergistic increases in neutralizing antibodies in preclinical studies using combinations of distinct proteins within a single vaccine formulation.[4]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein vaccines (multimeric protein technology)Subunit vaccineStructure-based vaccine design
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Citranvi Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citranvi Biosciences.